← All organizations

Krystal Biotech, Inc.

For profitContributed to NMEWebsite ↗

Also known as: Associate Director, Clinical Operations, Krystal Biotech | Krystal Biotech, Inc.

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

First marketed drug

First NDA

Last known activity

Jun 20, 2025

Timeline

2010s

Jun 1, 2015
Krystal Biotech, Inc.— Founded

2020s

May 19, 2023
beremagene geperpavec— NDA Organization
May 19, 2023
beremagene geperpavec— NDA Secondary Org

Drugs by trial phase (11 distinct, 14 trials)

Phase 3 (2 own, 0 via acquisition)

Phase 2 (5 own, 0 via acquisition)

Phase 1 (4 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (1)

beremagene geperpavec

Recent trials (15)

NCT07016750Lead sponsorPhase 3Jun 20, 2025
NCT06999733Lead sponsorPhase 1/Phase 2May 31, 2025
NCT06724900Lead sponsorPhase 1/Phase 2Nov 20, 2024
NCT06228326Lead sponsorPhase 1Apr 17, 2024
NCT06049082Lead sponsorPhase 1Jan 31, 2024
NCT05970497Lead sponsorEarly Phase 1Oct 31, 2023
NCT05735158Lead sponsorPhase 2Mar 31, 2023
NCT05504837Lead sponsorPhase 1Nov 30, 2022
NCT05504837Study directorPhase 1Nov 30, 2022
NCT05095246Lead sponsorPhase 1Oct 20, 2021
NCT04917874Lead sponsorPhase 3May 25, 2021
NCT04540900Lead sponsorPhase 1Sep 30, 2020
NCT04491604Lead sponsorPhase 3Aug 31, 2020
NCT04047732Lead sponsorPhase 1/Phase 2Sep 30, 2019
NCT03536143Lead sponsorPhase 1/Phase 2May 7, 2018

Details

Founded: Pittsburgh, PA, US Jun 1, 2015
First NDA: May 19, 2023
Last known activity: Jun 20, 2025

Designations held

Orphan drug